Treating thalassemia: from carrier status, transfusion and chelation to transplantation and newer therapies

Thalassemia comprises inherited disorders of globin production with presentations ranging from very few symptoms to a need for regular transfusion and multidisciplinary care. A positive genetic finding or a low red-cell volume does not automatically establish severe disease. The starting point is an integrated assessment of the blood count, hemoglobin analysis, genetic findings and clinical history: which alpha- or beta-related condition is present, whether the person is a carrier, and what anemia is currently doing to health. Origa et al.: Genetic Basis, Pathophysiology, and Diagnosis, TIF 2025

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Alpha-thalassemia includes carrier states and conditions such as hemoglobin H disease. Some non-deletional HbH forms carry greater transfusion needs and complication burdens than deletional forms. Severe alpha-thalassemia also involves specialized fetal and postnatal management. Beta-thalassemia has a range of genetic combinations and phenotypes, and HbE/beta-thalassemia can vary considerably. Calling every alpha form mild or every beta form lifelong transfusion-dependent would misrepresent this range. TIF 2023: α-Thalassaemia guideline, summary and recommendations
Allogeneic hematopoietic cell transplantation can establish donor hematopoiesis and offers a potential curative route for selected patients. Donor conditions, age, accumulated iron, organ health and center experience influence assessment. Conditioning, infection, graft rejection, graft-versus-host disease and reproductive effects belong in the discussion. The process cannot be reduced to a single replacement of marrow. Timely specialist review can help families consider an appropriate point for the decision using the actual health situation. Pinto et al.: Haematopoietic Cell Transplantation, TIF 2025
The regular schedule should include a route for unexpected illness. New marked weakness, fainting, significant breathing difficulty or symptoms during transfusion need timely assessment rather than waiting for the next routine appointment. Patients with particular drug-related or post-splenectomy risks may need additional written instructions. Ask the team to relate the emergency plan to the treatment actually being used.

Quick answer

Full guide

Establish which form of thalassemia needs care

Carrier status is different from a clinically significant thalassemia syndrome. Some carriers have mildly reduced hemoglobin or small red cells without needing the transfusion and chelation approach used for severe disease. A sudden worsening of anemia still requires consideration of iron deficiency, bleeding, infection or another cause. Thalassemia does not exclude coexisting iron deficiency, but anemia alone is not a reason to take iron indefinitely. Red-cell size cannot settle that decision by itself.

Alpha and beta are not simple labels for mild and severe

Alpha-thalassemia includes carrier states and conditions such as hemoglobin H disease. Some non-deletional HbH forms carry greater transfusion needs and complication burdens than deletional forms. Severe alpha-thalassemia also involves specialized fetal and postnatal management. Beta-thalassemia has a range of genetic combinations and phenotypes, and HbE/beta-thalassemia can vary considerably. Calling every alpha form mild or every beta form lifelong transfusion-dependent would misrepresent this range. TIF 2023: α-Thalassaemia guideline, summary and recommendations

Clinicians also describe transfusion-dependent and non-transfusion-dependent disease according to actual need. Non-transfusion-dependent does not mean that transfusion can never be necessary: infection, pregnancy or complications may change requirements. A regular program is considered using the sustained clinical situation. TIF addresses NTDT separately, reflecting why an assessment made early in life may need to be revisited as the person grows and circumstances change. Taher, Musallam and Cappellini: NTDT guideline introduction, third edition, 2023

Treatment aims include function, growth and organ protection

Hemoglobin is important, but care is not limited to improving a laboratory result. Children need attention to growth, activity and pubertal development. Adults may need support for work capacity and cardiac, hepatic, skeletal and reproductive health. The plan must account for anemia, ineffective erythropoiesis and iron burden, avoiding a focus on a short-term hemoglobin rise that overlooks longer-term damage.

Record the changes that matter in daily life: breathlessness on stairs, difficulty joining school activities, bone pain or poor appetite. These observations help connect laboratory findings to function. The 2025 TIF monitoring recommendations cover several organ systems, illustrating why care may involve different specialists over time rather than only contact with a service on transfusion day. TIF 2025: Summary of Monitoring Recommendations

Make a necessary transfusion program dependable

Regular red-cell transfusion is a foundation of transfusion-dependent beta-thalassemia care. Its purposes include correcting anemia and suppressing excessive ineffective erythropoiesis. The hematology team selects starting criteria, hemoglobin goals and intervals using age, symptoms, growth and complications. Do not postpone necessary transfusion independently to reduce iron input. Iron burden needs its own management, while inadequately treated chronic anemia can also cause harm. Shah, Wood and Maggio: Blood Transfusion, TIF 2025

Retain blood-group information, antibody history, previous reactions and details of actual transfusions. When changing hospitals, provide historical antibodies even if the most recent screen does not detect them. During transfusion, report chills, fever, chest or back discomfort and breathing problems immediately so staff can assess a possible reaction. Waiting until the bag has finished removes an opportunity for timely clinical action.

Assess iron using trends and the relevant organs

Repeated transfusion introduces iron, and some people without regular transfusions accumulate excess iron through increased intestinal absorption. Ferritin helps show a trend but can be affected by inflammation and does not directly quantify myocardial iron. Depending on the clinical situation, the team may use validated liver-iron or cardiac MRI assessment alongside functional investigations. One fall in ferritin does not establish that all organ iron is now safe. Porter, Wood and Coates: Iron Overload and Chelation, TIF 2025

Chelator selection and dose depend on age, iron burden, organ function, treatment practicality and adverse effects. Deferoxamine, deferasirox and deferiprone have different administration and monitoring requirements and should not be exchanged independently because they share a broad purpose. Discuss missed doses, gastrointestinal problems or work-schedule barriers openly. A sustainable plan is easier to develop when the clinician knows what is actually being taken.

Infrequent transfusion does not remove the need for follow-up

A person with NTDT may have few acute events over several years yet still need assessment of chronic anemia, iron, the spleen, bone health, thrombosis or other complications. The question is broader than whether the patient can manage without transfusion. Functional limitations and emerging problems also matter. A later need for more treatment may reflect changing requirements rather than an incorrect earlier diagnosis. TIF 2023: Ineffective Erythropoiesis and Anaemia in NTDT

Increasing breathlessness, substantial activity limitation, leg ulcers or new persistent bone pain should be discussed with a service familiar with thalassemia rather than left until an annual visit. Whether transfusion, medication or a local intervention is appropriate depends on the cause. Other chronic conditions may contribute, so every symptom should not be attributed to thalassemia without assessment.

Interpret newer medicines by indication and treatment objective

Luspatercept may be discussed to reduce transfusion burden in eligible adults with beta-thalassemia. Public Chinese prescribing information specifies regular transfusion and previous transfusion-volume conditions. It should not be described as suitable for every age or for all alpha- and beta-thalassemia. Continued treatment depends on response and safety. Reduced transfusion does not mean the inherited basis has disappeared or that iron surveillance is no longer required. 国家医保局公示：罗特西普2025申报文件，含国内说明书适应证信息

An important overseas update is oral mitapivat: FDA approved AQVESME in late 2025 for anemia in adults with alpha- or beta-thalassemia. The drug carries a significant hepatocellular-injury risk with required monitoring and a REMS program in the United States. Convenience of an oral formulation alone does not establish personal suitability. US approval should not be converted into a statement of Chinese authorization; the receiving service must verify the proposed local pathway. FDA: Approval of mitapivat for anemia in adults with alpha- or beta-thalassemia, December 2025 DailyMed: AQVESME mitapivat prescribing information

Transplantation offers potential cure with substantial considerations

Allogeneic hematopoietic cell transplantation can establish donor hematopoiesis and offers a potential curative route for selected patients. Donor conditions, age, accumulated iron, organ health and center experience influence assessment. Conditioning, infection, graft rejection, graft-versus-host disease and reproductive effects belong in the discussion. The process cannot be reduced to a single replacement of marrow. Timely specialist review can help families consider an appropriate point for the decision using the actual health situation. Pinto et al.: Haematopoietic Cell Transplantation, TIF 2025

Absence of a fully matched sibling does not make further consultation pointless, but neither does it make every alternative donor equally appropriate. The center should explain the conditions and evidence for its proposed approach. Ask what state is sought before transplantation, how existing organ problems are addressed and whether residual iron and other health issues will require treatment afterward. A smooth infusion day is not a complete measure of the pathway.

Gene-based treatment still involves collection and preparative care

Gene addition and gene editing generally use the patient's own hematopoietic cells, modified through a specific ex-vivo process and then returned. Collection, myeloablative conditioning, recovery and prolonged monitoring may still be required. The United States has authorized products including ZYNTEGLO and CASGEVY for defined beta-thalassemia settings, with different technologies and conditions. In July 2026, FDA expanded the US CASGEVY age indication, so older summaries may no longer describe the current US range. That expansion does not establish identical access in China. FDA: ZYNTEGLO product and prescribing information FDA: July 1, 2026 expansion of CASGEVY to patients aged 2 years and older with SCD or TDT

Early Chinese CS-101 base-editing results were published in 2026. A small study with limited follow-up provides information for further research, not proof of universal cure, absence of long-term risk or routine marketing authorization. When reading a report, examine the number actually treated, the definition of transfusion independence, preparative-treatment risks and continuing follow-up. A success headline is less informative than those details for an individual decision. Lai et al.: Clinical application of base editing for treating β-thalassaemia, Nature 2026

Treat particular complications for a defined reason

Splenic enlargement, gallstones, extramedullary hematopoiesis and infection may require specific assessment. Splenectomy is not a routine answer to every enlarged spleen because long-term infection and thrombosis risks must be weighed. If surgery is proposed, ask which problem it is intended to solve, whether another approach is applicable and how prevention and monitoring will continue afterward. Aydinok et al.: Other Complications, TIF 2025

Slow growth, delayed puberty, glucose disturbances and bone problems also deserve more than nutritional supplements alone. TIF's endocrine and bone chapter supports investigation and management of the actual abnormality. Children benefit from continuous growth records, and adults should report menstrual, sexual-function, bone-pain or fracture concerns. The objective is to identify avoidable long-term harm before a major loss of function becomes the first reason for investigation. Casale et al.: Growth Abnormalities, Endocrine, and Bone Disease, TIF 2025

Nutrition and family support should sustain the care plan

Adequate nutrition remains necessary for development and daily activity. Patients should not adopt a severely restricted diet solely to avoid iron. Folate, vitamin D and other supplements should be considered in relation to intake and investigations, with particular care before adding iron. TIF's nutrition discussion places dietary care alongside medical treatment; supplements cannot replace needed transfusion or chelation. Fung and Angastiniotis: Nutrition, TIF 2025

Relatives can help organize visits and medicine records while allowing the patient to take part in decisions. Over time, children can learn to explain their medicines, transfusion history and routes for help. Moving to adult services, education, employment or planning a family may introduce practical difficulties that deserve attention at clinic. Discussing a specific barrier is often more useful than repeatedly telling someone to adhere without understanding what makes the plan hard to follow.

Build a plan that can continue across hospitals

China's National Health Commission has established a thalassemia prevention and care collaboration network linking screening, diagnosis, treatment and patient management. Official hospital routes can help identify the relevant specialty and referral requirements. Network membership does not mean that every member provides every new medicine, gene therapy or immediate bed. Confirm the actual service and how transfusion and chelation will remain continuous around any journey. 国家卫生健康委：全国地中海贫血防控协作网，2023

For a first consultation, bring genetic and hemoglobin-analysis reports, complete transfusion and antibody histories, chelator use, iron MRI results and available organ assessments. Ask the clinician to identify the most pressing current problems and the next investigation or review for each. Thalassemia care often spans many years. A clear plan that can be delivered and updated as the patient's condition changes is more useful than focusing on a single post-treatment number.

Agree on how urgent changes will be handled

The regular schedule should include a route for unexpected illness. New marked weakness, fainting, significant breathing difficulty or symptoms during transfusion need timely assessment rather than waiting for the next routine appointment. Patients with particular drug-related or post-splenectomy risks may need additional written instructions. Ask the team to relate the emergency plan to the treatment actually being used.

Reviewing the plan periodically gives the patient an opportunity to discuss benefits, difficulties and priorities. The appropriate balance between supportive treatment, disease-modifying medicine and a potentially curative pathway can differ across people and over time. The decision should remain connected to the confirmed diagnosis, clinical state and care that can be provided reliably.